OPtimisation of Surgical Repair for Treating Insufficiency of the MItral Valve - Safety and Effectiveness Evaluation

Inclusion Criteria: \- Patients must meet ALL the following inclusion criteria : 1. with primary or secondary mitral regurgitation recorded by TTE and confirmed during TEE where surgery for mitral valve repair is required with indications consistent with AHA/ACC and ESC/EACTS guidelines : 1. primary (degenerative) : severe MR grade parameters (R Vol and EROA measured by PISA methods): * EROA regurgitant \>60 ml and * Vena contracta width \> 7mm and * Regurgitant fraction \>50% 2. Secondary (functional) : severe MR (EROA ≥30 mm²; R Vol \> 30ml) may differ from the primary MR and are based on the prognostic value of these thresholds to predict the poor outcome, or for patients undergoing CABG 2. with LVEF ≥ 30% 3. in satisfactory condition, based on the physical examination and investigator's experience, with a life expectancy above one year after the intervention 4. with or without concomitant procedures as: CABG, other valve repair/replacement, pacemaker implantation, exclusion of left appendage (with device or surgically) and Maze (or PVI) procedure 5. willing to sign the informed consent; 6. able and willing to comply with all clinical investigation requirements, including the required study follow-up visits Exclusion Criteria: * Patients will be excluded if ANY of the following conditions are present: 1. of age \< 21 years; 2. with echocardiographic measurements predicting SAM 1. LVEDD \< 45 mm 2. C-Sd \< 25mm (distance from the septum to the mitral valve coaptation point) 3. Basal-IVDd \> 15 mm 4. aorto-mitral angle \< 120° 5. pre-repair posterior leaflet height \> 15 mm 3. with cardiogenic shock; 4. with active endocarditis (or having had active endocarditis in the last three months); 5. with active myocarditis; 6. with heavily calcified mitral annulus; 7. with mitral stenosis; 8. unable to take anticoagulation medications; 9. with a known untreatable allergy to contrast media or nickel; 10. with a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy shorter than 1 year, or for whom the implant of the device produces an unacceptable increase of risk; 11. with contraindication to transoesophageal echocardiography; 12. with contraindication to cardiopulmonary bypass; 13. who are pregnant or breast-feeding women; 14. involved in any other clinical investigation for drugs or devices; 15. unable to understand and sign the ICF in absence of legal protection; 16. unable to read and write;